Nifty top gainers today, July 29: Jio Financial Services, Reliance Industries, Larsen & Toubro, Asian Paints and more
Indian markets ended on a firm note on July 29, with the Nifty 50 closing at 24,821.10, up 0.57%. The Sensex also advanced 446.93 points to settle at 81,337.95, supported by broad-based buying across key sectors.
Several heavyweight stocks in the Nifty 50 posted notable gains. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on July 29 Jio Financial Services closed at ₹322.00, up 4.8%.
Reliance Industries ended at ₹1,416.60, rising 2.1%.
Larsen & Toubro settled at ₹3,488.00, gaining 1.9%.
Asian Paints closed at ₹2,401.50, up 1.8%.
Eicher Motors ended the session at ₹5,479.50, advancing 1.7%.
Apollo Hospitals Enterprise closed at ₹7,469.00, up 1.5%.
Adani Ports and Special Economic Zone settled at ₹1,397.00, gaining 1.5%.
IndusInd Bank closed at ₹813.80, rising 1.5%.
Coal India ended at ₹383.70, up 1.4%.
Tata Motors closed at ₹692.40, rising 1.4%.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash Asian PaintsJio Financial ServicesLarsen & ToubroReliance Industries
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
41 minutes ago
- CNBC
Trump turns up the heat on India — Tariffs & Russia penalty explained
CNBC's Sri Jegarajah and CNBC TV-18's Parikshit Luthra analyze the potential impact of a 25% tariff on Indian exports and a penalty related to purchases of Russian oil and defense products. The Indian government has reiterated its commitment to protecting national interests in ongoing trade discussions.
NBC News
3 hours ago
- NBC News
Ancient Buddha relics returned to India after $13 million auction is canceled
HONG KONG — A collection of ancient gems linked to Buddha's remains has been repatriated to India after authorities slammed their planned auction by Sotheby's in Hong Kong. 'A joyous day for our cultural heritage!' Indian Prime Minister Narendra Modi said Wednesday in a post on X. The Piprahwa Gems were sold to the Indian conglomerate Godrej Industries Group, which will put the dazzling collection 'on public display for years to come,' Sotheby's said in a statement Thursday. The auction house declined to reveal how much Godrej paid for the gems. 'Due to the confidential nature of private sales, the final sale price will not be disclosed,' Sotheby's told NBC News. The 334 gems had been expected to net upward of 100 million Hong Kong dollars ($12.9 million) at auction. The gemstones are part of a cache of more than 1,800 artifacts, mostly housed at the Indian Museum in Kolkata. Critics of the planned auction of the gems, which British colonial landowner William Claxton Peppé dug up on his northern Indian estate in 1898, said it was offensive to the world's 500 million Buddhists and a violation of Indian and international law and United Nations conventions. Many Buddhists believe the gemstones, named after the town in what is now the Indian state of Uttar Pradesh, where they were buried in a stupa, or funerary monument, around 200 to 240 B.C., are imbued with the presence of Buddha, on top of whose cremated remains the gemstones were said to be enshrined. 'It would make every Indian proud that the sacred Piprahwa relics of Bhagwan Buddha have come home after 127 long years,' Modi said, referring to Buddha as a god in Hindi. 'These sacred relics highlight India's close association with Bhagwan Buddha and his noble teachings,' he added. Sotetheby's postponed the planned auction of the gems in May after the Indian government threatened legal action and demanded their repatriation. The Indian government said at the time that Peppé's great-grandson, Chris Peppé, a TV director and film editor based in Los Angeles, lacked the authority to sell the gems. New Delhi also accused Sotheby's of 'participating in continued colonial exploitation' by facilitating the sale and said that the gems must be returned to India if Peppé no longer wished to be their custodian. 'I hope they will go to someone who really values them,' Peppé wrote in a February piece for Sotheby's accompanying the auction catalogue. They were put on public exhibition in Hong Kong in the days leading up to the auction in three glass cases, containing shimmering penny-sized silver and gold-leaf stars embossed with symbols. They also include pearls, beads and flowers cut from precious stones, including amethyst, topaz, garnet, coral and crystal. Sotheby's later announced the auction had been postponed 'with the agreement of the consignors,' three descendants of the British colonial landowner who excavated them. On Thursday, the auction house said it had 'facilitated the return' of the gems to India, thanking the Peppé family. 'This completes our active search over the past two months to identify the best possible custodian for the Gems,' Sotheby's said.
Business Upturn
4 hours ago
- Business Upturn
Why Dr. Reddy's shares are down nearly 2% today? Explained
By Aditya Bhagchandani Published on July 31, 2025, 09:44 IST Shares of Dr. Reddy's Laboratories Ltd dropped nearly 2% to ₹1,269.70 in early trade on Wednesday, reacting sharply to the overnight announcement by former U.S. President Donald Trump regarding the imposition of 25% tariffs on Indian exports to the United States. The move includes a yet-unspecified penalty for India's continued energy and defense dealings with Russia. The stock was among the worst-hit in the pharmaceutical space as investors digested the potential impact on generic drug exports, which constitute a major portion of India's pharmaceutical trade with the U.S. Pharma Exports at Risk? The United States is a critical market for Indian drugmakers. In fact, Dr. Reddy's derives 46% of its revenue from the U.S., making it highly sensitive to any changes in trade policy. While pharmaceuticals are currently exempt from the reciprocal tariff list (announced in April), officials from the White House confirmed to CNBC-TV18 that these exemptions may soon be lifted. The Department of Commerce's Section 232 investigation into Indian generic drug exports has now concluded, and according to Trump's latest statement, tariffs on pharma 'are coming soon.' Currently, India pays zero tariffs on generic drug exports to the U.S. If the proposed 25% tariff is applied to this sector, Indian companies may have to choose between: Passing the cost onto U.S. consumers , making Indian generics less price-competitive Reevaluating U.S. portfolios , withdrawing lower-margin or loss-making products Manufacturing in the U.S., which may offer no cost advantage for generics Broader Impact Across the Pharma Space Besides Dr. Reddy's, stocks likely to remain under pressure include: Sun Pharma (33% U.S. exposure) Aurobindo Pharma (45%) Gland Pharma (53%) Divi's Laboratories Cipla, Lupin, and Biocon Who Might Buck the Trend? Pharma firms and healthcare providers with a domestic business focus or minimal U.S. exposure may remain resilient: Ajanta Pharma, Eris Lifesciences, Torrent Pharma Apollo Hospitals, Fortis Healthcare, Aster DM Diagnostics players like Dr. Lal Pathlabs, Metropolis Final Word Though Indian pharma exports are not yet officially included in the tariff list, Trump's statements have created uncertainty for the sector. Until there is clarity from the U.S. Trade Representative or India's Commerce Ministry, investor sentiment around high U.S.-exposed pharma names may remain volatile. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
